Dapagliflozin Reduces Hospitalizations Among Patients With CKD

Dapagliflozin Reduces Hospitalizations Among Patients With Ckd

TUESDAY, Dec. 6, 2022 (HealthDay News) — For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.

Meir Schechter, M.D., from the University of Groningen in the Netherlands, and colleagues determined the effects of dapagliflozin on first hospitalizations and all hospitalizations in a post-hoc analysis of a randomized clinical trial. A total of 4,304 adults with an estimated glomerular filtration rate (eGFR) of 25 to 75 mL/min/1.73 m2 and urinary albumin-creatinine ratio of 200 to 5,000 mg/g, with or without type 2 diabetes, were randomly assigned to receive either dapagliflozin 10 mg once daily or matching placebo.

The researchers identified 2,072 hospitalizations among 1,224 (28.4 percent) participants during a median follow-up of 2.4 years. Dapagliflozin reduced the risk for a first hospitalization and all hospitalizations compared with placebo (hazard ratio, 0.84 and rate ratio, 0.79, respectively). No evidence was seen for the effects of dapagliflozin on first and all hospitalizations varying by baseline presence of type 2 diabetes. The rate of admissions due to cardiac disorders, renal and urinary disorders, metabolism and nutrition disorders, and neoplasms was reduced with dapagliflozin compared with placebo.

“These findings highlight additional benefits of dapagliflozin beyond those seen for cardiovascular and kidney events, all-cause and cause-specific mortality, eGFR slope, and albuminuria and should be considered when evaluating the totality of evidence favoring provision of dapagliflozin to patients with CKD,” the authors write.

The study was funded by AstraZeneca, the manufacturer of dapagliflozin.

Abstract/Full Text (subscription or payment may be required)